Receipt of Disease-Modifying Antirheumatic Drugs Among Patients With Rheumatoid Arthritis in Medicare Managed Care Plans

被引:108
|
作者
Schmajuk, Gabriela [1 ]
Trivedi, Amal N. [2 ]
Solomon, Daniel H. [3 ]
Yelin, Edward [4 ]
Trupin, Laura [4 ]
Chakravarty, Eliza F. [1 ]
Yazdany, Jinoos [4 ]
机构
[1] Stanford Univ, Dept Med, Div Rheumatol, Stanford, CA 94304 USA
[2] Brown Univ, Dept Community Hlth & Med, Providence, RI 02912 USA
[3] Harvard Univ, Brigham & Womens Hosp, Dept Med, Div Rheumatol, Boston, MA 02115 USA
[4] Univ Calif San Francisco, Dept Med, Div Rheumatol, San Francisco, CA USA
来源
基金
美国医疗保健研究与质量局; 美国国家卫生研究院;
关键词
QUALITY-OF-CARE; HEALTH PLANS; DISPARITIES; OUTCOMES; DATABASE; COST; BENEFICIARIES; NEIGHBORHOOD; MEDICATIONS; AMERICAN;
D O I
10.1001/jama.2011.67
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context In 2005, the Healthcare Effectiveness Data and Information Set (HEDIS) introduced a quality measure to assess the receipt of disease-modifying antirheumatic drugs (DMARDs) among patients with rheumatoid arthritis (RA). Objective To identify sociodemographic, community, and health plan factors associated with DMARD receipt among Medicare managed care enrollees. Design, Setting, and Participants We analyzed individual-level HEDIS data for 93 143 patients who were at least 65 years old with at least 2 diagnoses of RA within a measurement year (during 2005-2008). Logistic regression models with generalized estimating equations were used to determine factors associated with DMARD receipt and logistic regression was used to adjust health plan performance for case mix. Main Outcome Measures Receipt or nonreceipt of DMARD. Results The mean age of patients was 74 years; 75% were women and 82% were white. Overall performance on the HEDIS measure for RA was 59% in 2005, increasing to 67% in 2008 (P for trend <.001). The largest difference in performance was based on age: patients aged 85 years and older had a 30 percentage point lower rate of DMARD receipt (95% confidence interval [CI], -29 to -32 points; P<.001), compared with patients 65 to 69 years of age, even after adjusting for other factors. Lower percentage point rates were also found for patients who were men (-3 points; 95% CI, -5 to -2 points; P<.001), of black race (-4 points; 95% CI, -6 to -2 points; P<.001), with low personal income (-6 points; 95% CI, -8 to -5 points; P<.001), with the lowest zip code-based socioeconomic status (-4 points; 95% CI, -6 to 2 points; P<.001), or enrolled in for-profit health plans (-4 points; 95% CI, -7 to 0 points; P<.001); and in the Middle Atlantic region (-7 points; 95% CI, -13 to -2 points; P<.001) and South Atlantic regions (-11 points; 95% CI, -20 to -3 points; P<.001) as compared with the Pacific region. Performance varied widely by health plan, ranging from 16% to 87%. Conclusions Among Medicare managed care enrollees carrying a diagnosis of RA between 2005 and 2008, 63% received a DMARD. Receipt of DMARDs varied based on demographic factors, socioeconomic status, geographic location, and health plan. JAMA. 2011;305(5):480-486 www.jama.com
引用
收藏
页码:480 / 486
页数:7
相关论文
共 50 条
  • [31] Disease-Modifying Antirheumatic Drugs Increase Serum Adiponectin Levels in Patients With Rheumatoid Arthritis
    Cansu, Baris
    Cansu, Dondu U.
    Kasifoglu, Timucin
    Gulbas, Zafer
    Korkmaz, Cengiz
    [J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2011, 17 (01) : 14 - 17
  • [32] INDICATIONS FOR STARTING OR CHANGING DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID-ARTHRITIS PATIENTS
    YANNI, G
    CHOY, EHS
    KINGSLEY, GH
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1993, 11 (06) : 693 - 693
  • [33] Factors Associated with the Use of Biologic Disease-modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
    Hosseini, Roya
    Fawaz, Souhiela
    Seoane-Vazquez, Enrique
    [J]. ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2595 - 2595
  • [34] SURVIVAL ANALYSIS OF DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN SPANISH RHEUMATOID-ARTHRITIS PATIENTS
    DELAMATA, J
    BLANCO, FJ
    GOMEZREINO, JJ
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 1995, 54 (11) : 881 - 885
  • [35] The perioperative use of synthetic and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
    Gregory, Fleury
    Sylvano, Mania
    Didier, Hannouche
    Cem, Gabay
    [J]. SWISS MEDICAL WEEKLY, 2017, 147
  • [36] Use of Disease-modifying Antirheumatic Drugs After Cancer Diagnosis in Rheumatoid Arthritis Patients
    Joo, Young Bin
    Jung, Seung Min
    Park, Yune-Jung
    Kim, Ki-Jo
    Park, Kyung-Su
    [J]. JOURNAL OF RHEUMATIC DISEASES, 2022, 29 (03): : 162 - 170
  • [37] Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis
    Lacaille, Diane
    Guh, Daphne P.
    Abrahamowicz, Michal
    Anis, Aslam H.
    Esdaile, John M.
    [J]. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2008, 59 (08): : 1074 - 1081
  • [38] Adherence to Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis A Narrative Review of the Literature
    Salt, Elizabeth
    Frazier, Susan K.
    [J]. ORTHOPAEDIC NURSING, 2010, 29 (04) : 260 - 275
  • [39] FACTORS ASSOCIATED WITH BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS UTILIZATION IN RHEUMATOID ARTHRITIS PATIENTS
    Hosseini, R.
    Brown, L.
    Rodriguez-Monguio, R.
    Seoane-Vazquez, E.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S453 - S453
  • [40] Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis
    Grijalva, Carlos G.
    Chung, Cecilia P.
    Arbogast, Patrick G.
    Stein, Charles M.
    Mitchel, Edward F., Jr.
    Griffin, Marie R.
    [J]. MEDICAL CARE, 2007, 45 (10) : S66 - S76